 A randomised, placebo-controlled, 4-period, incomplete block, crossover study of 7 days dosing of intranasal GW784568X 100mcg, 200mcg and 400mcg od, fluticasone propionate 200mcg od and placebo blinded for GW784568X vs placebo to evaluate the efficacy and safety using an environmental chamber in male subjects with allergic rhinitis 